Objective: We aimed to examine the association of APOE e genotype with MRI markers of cerebrovascular disease (CVD): white matter hyperintensities, brain infarcts, and cerebral microbleeds.
The e4 allele of the APOE gene is a major risk factor for dementia and Alzheimer disease (AD). [1] [2] [3] [4] [5] [6] The association of APOE with cerebrovascular disease (CVD) is more controversial. 7 APOE e4 is a risk factor for cerebral amyloid angiopathy (CAA), a major determinant of intracerebral hemorrhage (ICH) in older individuals. 1 Recent data from the International Stroke Genetics Consortium suggest an association of APOE e4 with an increased risk of ICH, mostly lobar, 8 and an association of the APOE e2 allele with an increased risk and size of lobar ICH. 8, 9 Whether the epsilon polymorphism is also associated with an increased risk of ischemic stroke and MRI markers of CVD is unclear. 7 MRI markers of CVD-white matter hyperintensities (WMH), brain infarcts (BI), and cerebral microbleeds (CMB)-are powerful predictors of stroke and dementia. [10] [11] [12] [13] They are highly prevalent in older community-dwelling persons, [14] [15] [16] and can be assessed noninvasively and quantitatively in large population-based samples. Dissecting the relationship between APOE and MRI markers of CVD could provide important clues to the mechanisms underlying the association between APOE and risk of dementia. Indeed, although APOE is involved in modulating the metabolism and accumulation of amyloid b (Ab), the precise mechanisms underlying its relationship with the risk of dementia are not fully understood. 1 Whether the latter is also partly mediated by CVD, a powerful determinant of dementia risk, could be important for optimizing prevention strategies.
Our aim is to provide a systematic review and meta-analysis of studies evaluating the relationship of APOE e genotype with MRI markers of CVD.
METHODS Search strategy and selection criteria. A research fellow and a neurologist identified references through searches of PubMed from 1966 to June 14, 2012, using predefined search terms. We also identified articles by reviewing reference lists of relevant articles and through searches of the authors' files. In addition, some studies (3C-Dijon, 17 Framingham Heart Study [FHS], 18, 19 Sydney Memory and Ageing Study [Sydney-MAS] 20 ) provided unpublished data for this review (methods e-1 on the Neurology ® Web site at www.neurology.org).
We included studies testing the association of APOE genotype with at least one of the 3 MRI markers of CVD (WMH, BI, CMB), limited to those in adults.
The following were exclusion criteria: 1) evaluation of markers of CVD by CT scan only; 2) sample size ,50 individuals; 3) studies evaluating separately the effect of each single nucleotide polymorphism comprising the APOE e4 allele (methods e-1).
Data extraction. We extracted the following data from the studies: sample size, study population (general population vs high-risk individuals), mean age, MRI characteristics and sequences, definition of the markers of CVD, measure of the association between APOE genotype and MRI markers, APOE genotypes used as reference, and adjustment variables when applicable. For measures of association between APOE genotype and MRI markers, we recorded odds ratios (ORs) for dichotomous MRI markers and standardized mean differences (measuring the difference in units of SD) or regression coefficients for continuous MRI markers; when none was available, raw numbers or mean values and SD by genotype group were used to compute OR or standardized mean differences, respectively. When none could be extracted, authors were contacted to provide those. If measures of association remained unavailable thereafter, qualitative results were reported. Two authors (S.D., S. Schilling) extracted the above information from each study, resolving any disagreement by discussion.
Variable definition. The study population was defined as "general population" when the analysis was performed in a communitybased setting or on participants described as "healthy individuals," and as "high-risk population" when the study was conducted on persons selected for the presence of prevalent diseases such as cognitive impairment, stroke, depression, dementia, hypertension, or leukoaraiosis (or in populations enriched by design in persons with such prevalent disease). We excluded studies on white matter lesions occurring in inflammatory or neurodegenerative conditions and studies on WMH in monogenic cerebrovascular diseases (methods e-2).
In cross-sectional studies, WMH burden was studied as a dichotomized variable (presence vs absence or extensive vs low WMH burden), or as a continuous variable (grade from a semiquantitative visual scale or quantitatively measured volume). When computing ORs from raw numbers for WMH grades, we used the most severe grade vs all others. Some studies distinguished periventricular WMH (PVH) and deep WMH (DWMH). Whenever possible, we used results for global WMH, but when only PVH and DWMH were available, we used PVH in our primary meta-analysis and ran a secondary analysis using DWMH instead of PVH (methods e-2). In longitudinal studies, change in WMH grade or volume was retrieved. BI (or CMB) were defined by the presence of one or more BI (or CMB) vs none. Some studies distinguished CMB according to their location (lobar vs deep or infratentorial). In longitudinal studies, presence of incident CMB was evaluated.
Table e-1 details study quality criteria, including sample size, whether reference group and adjustment variables were specified, whether allele frequencies were reported for APOE e4 and APOE e2, type of WMH quantification, WMH measure used for analysis, and whether methods for differentiating BI from dilated perivascular spaces were specified.
Statistical analyses. Meta-analysis was performed when at least 3 studies were available for the same outcome. Associations of WMH, BI, and CMB with the following genotype groups were summarized: APOE e4 carriers (e41), homozygous APOE e4 carriers (e44), and APOE e2 carriers (e21) (methods e-3). The reference group was APOE e4 noncarriers (APOE e42) and APOE e2 noncarriers (APOE e22) in most studies (some excluded APOE e24 carriers), and APOE e33 in the others. When several adjustment models were used, we included the least adjusted one. For quantitative measures of WMH burden, we used models accounting for total intracranial volume whenever available. We also ran secondary analyses using the most adjusted data. When both continuous and dichotomous measurements of WMH burden were available, we used the continuous data.
For BI and CMB, we calculated pooled ORs using an inverse variance-weighted meta-analysis. A fixed-effects meta-analysis was used in the absence of heterogeneity and a random-effects model if heterogeneity between studies was significant (heterogeneity p value ,0.05 or I 2 .50%). For WMH burden, we combined results from all studies using a sample size-weighted z score-based meta-analysis. This approach accounts for the fact that WMH burden was measured on different scales and analyzed either quantitatively or qualitatively across studies (methods e-3). We also calculated pooled ORs or standardized mean differences separately for studies using dichotomous or continuous measures of WMH burden, using an inverse varianceweighted meta-analysis. In secondary analyses, we ran a sample sizeweighted z score-based meta-analysis for associations with continuous measures of WMH burden, as studies used different quantitative or semiquantitative measurements, and performed separate meta-analyses in the general population and in high-risk populations.
We applied a Bonferroni correction for multiple testing, accounting for the 3 tested phenotypes (WMH, BI, and CMB), yielding a significance threshold of p , 0.0166, although this may be conservative given the strong correlation between WMH, BI, and CMB. 12, 21, 22 Meta-analysis was performed using the Cochrane RevMan (version 5.1) software (http://www.cc-ims.net/RevMan/current. htm) for inverse variance-weighted meta-analyses and R (http:// cran.r-project.org) for sample size-weighted z score-based metaanalyses. Graphs were obtained using the rmeta package in R (http://cran.r-project.org/web/packages/rmeta/index.html).
RESULTS
The initial literature search identified 237 articles, of which 44 met the inclusion criteria. We excluded 5 articles because they overlapped with another larger study and added unpublished data from 3 studies (3C-Dijon, FHS, and Sydney-MAS). Hence, the total number of articles included in this systematic review was 42, comprising 29,965 subjects. APOE e4 and MRI markers of CVD. APOE e4 and WMH.
APOE e41 and WMH. When combining the 27 available studies (n 5 18,309, 14,491 in the general population and 3,818 in high-risk populations, tables e-2 and e-3) 2,3,5,11,13,21,23-41 (FHS, Sydney-MAS, unpublished data) in a sample size-weighted z score-based meta-analysis, APOE e41 was significantly associated with increasing WMH burden: p z score 5 0.0034.
A meta-analysis restricted to studies using continuous WMH burden and providing standardized mean differences (n 5 8,917, 8,405 in the general population and 512 in high-risk populations) 2, 3, 11, 24, 26, 30, 33, 35, 36, 38, 39 (Sydney-MAS, unpublished data) yielded a borderline nominal association of APOE e41 with increasing WMH burden: pooled standardized mean difference 5 0.047 (95% confidence interval 0.0006, 0.094) (p 5 0.05) (p z score 5 0.0631) ( figure 1A ). When adding studies using continuous WMH but providing regression coefficients (n 5 4,004) 5,40,41 (FHS, unpublished data), in a sample size-weighted z score-based metaanalysis, the association was p z score 5 0.0028.
Analyzing studies using dichotomized WMH burden assessment (n 5 5,282, 3,627 in the general population and 1,655 in high-risk populations) 21, 23, 25, [27] [28] [29] 31, 32, 34, 37 revealed no significant association of APOE e41 with large WMH burden: pooled OR 5 1.07 (0.93, 1.22) (p 5 0.34) (p z score 5 0.39) ( figure 1A ). Results were similar after adding one study using a 3-class variable for WMH with ordinal logistic regression (n 5 106, p z score 5 0.44). 13 Four small studies (n 5 420 in high-risk populations) could not be included in this meta-analysis e21,e22,e25,e28 : one found a significant association between APOE e41 and WMH. e22 APOE e41 and WMH progression. Two studies (n 5 2,304 in the general population) did not report any significant association between APOE e41 and WMH progression (table e-4). e32,e33 APOE e44 and WMH. When meta-analyzing 12 studies (n 5 7,494, 6,254 in the general population, 1,240 in high-risk populations, tables e-2 and e-3) 3, 11, 13, 21, 28, 30, 31, [37] [38] [39] (Sydney-MAS, FHS, unpublished data) in a sample size-weighted meta-analysis, APOE e44 was significantly associated with increasing WMH burden: p z score 5 0.0030.
Combining studies using continuous WMH and providing standardized mean differences (n 5 2,447, 2,119 in the general population, 328 in high-risk populations) 3,11,30,38,39 (Sydney-MAS, unpublished data) yielded a significant association between APOE e44 and increasing WMH burden: pooled standardized mean difference 5 0.41 (0.17, 0.65) (p 5 0.0009) (p z score 5 0.0016) ( figure 1B ). When adding one study providing regression coefficients (n 5 1,574) (FHS, unpublished data), the association was still nominally significant: p z score 5 0.032.
Studies examining WMH as a dichotomous variable (n 5 3,399, 2,487 in the general population, 912 in high-risk populations) 21, 28, 31, 37 showed a nominally significant association of APOE e44 with increasing WMH burden: pooled OR 5 1.63 (1.004, 2.64) (p 5 0.048) (p z score 5 0.046) ( figure 1B) . Adding one study using a 3-class WMH variable with ordinal logistic regression (n 5 74) did not modify this association (p z score 5 0.039). 13 One study (n 5 56 in high-risk populations) could not be included in this meta-analysis and reported a significant association between APOE e44 and increasing WMH. e22 APOE e44 and WMH progression. One longitudinal study from the general population reported a significant association of APOE e44 with worsening WMH burden (table e-4). 3 APOE e4 and BI. APOE e41 and BI. In a meta-analysis including 7 studies (n 5 8,223, 8,005 in the general population, 218 in high-risk populations) 4, 11, 24, 34, 37 (3C-Dijon, FHS, unpublished data), APOE e41 was not associated with BI: pooled OR 5 1.03 (0.90, 1.18) (p 5 0.67) (figure e-1, table e-5). One study (n 5 82 in high-risk populations) could not be included in this meta-analysis and did not report any association between APOE e41 and BI. 32 APOE e44 and BI. APOE e44 was not associated with BI in a meta-analysis including 4 studies (n 5 6,029, 5,956 in the general population, 73 in highrisk populations) 11, 37 (3C-Dijon, FHS, unpublished data): pooled OR 5 0.86 (0.29, 2.52) (p 5 0.79) (figure e-2, table e-5).
We did not identify longitudinal studies assessing the relationship between APOE genotype and incident BI.
APOE e4 and CMB. APOE e41 and CMB. Meta-analyzing 9 studies (n 5 6,698, 5,387 in the general population and 1,311 in high-risk populations, tables e-6 and e-7) 11, 12, 21, 22, 34, [42] [43] [44] (FHS, unpublished data) yielded a significant association of APOE e41 with an increased risk of CMB: pooled OR 5 1.24 (1.07, 1.43) (p 5 0.004) ( figure 2A) , which was significant for lobar (n 5 3,689, pooled OR 5 1.34 [1.09, 1.64], p 5 0.006) but not deep CMB (n 5 3,777, pooled OR 5 1.15 [0.89, 1.49], p 5 0.29). 12, 21, 43, 44 Of note, results were significant in the general population but not in the smaller subset of studies performed in highrisk populations, comprising participants with diverse preexisting conditions (ICH, cerebral ischemia, hypertension, AD, other neurologic disorders). Meta-analysis of studies testing the association between APOE e41 and white matter hyperintensities burden and between APOE e44 and white matter hyperintensities burden (A) Meta-analysis of studies testing the association between APOE e41 and white matter hyperintensities (WMH) burden: fixed-effects inverse varianceweighted meta-analysis for studies on APOE e41 and continuous WMH (providing standardized mean differences) (heterogeneity test: I² 5 24%, p 5 0.20) (i); secondary meta-analyses in the general population (heterogeneity test: I² 5 39%, p 5 0.11) and in high-risk populations (heterogeneity test: I² 5 0%, p 5 0.63) also using a fixed-effects inverse variance-weighted meta-analysis. Fixed-effects inverse variance-weighted meta-analysis for APOE e41 and dichotomized WMH (heterogeneity test: I² 5 0%, p 5 0.65) (ii); secondary meta-analyses in the general population (heterogeneity test: I² 5 0%, p 5 0.46) and in high-risk populations (heterogeneity test: I² 5 0%, p 5 0.74) also using a fixed-effects inverse variance-weighted meta-analysis. Secondary analyses using randomeffects meta-analyses yielded similar results (figure e-4). Additive model: additive genetic model relating the number of copies of the e4 allele to WMH volume. (B) Meta-analysis of studies testing the association between APOE e44 and WMH burden. Fixed-effects inverse variance-weighted meta-analysis on WMH burden studied as a continuous (heterogeneity test: I² 5 8%, p 5 0.36) (i) and as a dichotomous variable (heterogeneity test: I² 5 0%, p 5 0.93) (ii). For secondary analyses using a random-effects model, see figure e-5. APOE e41 5 APOE e4 carrier status; FHS 5 Framingham Heart Study; HTN 5 hypertension; OR 5 odds ratio; p 5 p value from inverse variance-weighted meta-analysis; p z score 5 p value from sample size-weighted z score-based meta-analysis; SMD 5 standardized mean deviation; Sydney MAS 5 Sydney Memory and Ageing Study. APOE e44 and CMB. APOE e44 was significantly associated with an increased risk of CMB in a metaanalysis combining 6 studies (n 5 5,158, 4,798 in the general population, 360 in high-risk populations, tables e-6 and e-7) 11,12,21,22,42 (FHS, unpublished data): pooled OR 5 1.87 (1.26, 2.78) (p 5 0.002) ( figure 2B) . APOE e4 and incident CMB. One study (n 5 654 in the general population) e41 reported a significant association of APOE e44 but not APOE e41 with incident lobar CMB (table e-8). Another study (n 5 197 in high-risk populations) did not report any association between APOE e41 and incident CMB (table e-8). e42 APOE e2 and MRI markers of CVD. APOE e2 and WMH.
APOE e21 and WMH. In a sample size-weighted metaanalysis including 9 studies (n 5 6,669, 5,282 in the general population, 1,387 in high-risk populations, table e-9) 21, 23, 31, 34, 35, 39 (3C-Dijon, FHS, Sydney-MAS, unpublished data), APOE e21 was significantly associated with increasing WMH burden: p z score 5 0.00053.
Combining studies using WMH as a continuous variable (n 5 2,708, all general population) 35, 39 (3C-Dijon, Sydney-MAS, unpublished data) showed a nonsignificant trend of association between APOE e21 and WMH burden: pooled standardized mean difference 5 0.03 (20.01, 0.07) (p 5 0.20) (p z score 5 0.07) ( figure 3A) . This was similar when adding one study using continuous WMH but providing regression coefficients (n 5 2,353) (FHS, unpublished data), p z score 5 0.09. In a meta-analysis of 4 studies examining WMH as a dichotomous variable (n 5 1,608, 221 in the general population, 1,387 in high-risk populations), 21, 23, 31, 34 APOE e21 was significantly associated with increasing WMH burden: pooled OR 5 1.80 (1.35, 2.42) (p 5 0.00008) (p z score 5 0.00011) ( figure 3A) .
APOE e2 and BI. APOE e21 and BI. In a meta-analysis including 4 studies (n 5 4,446, 4,345 in the general population, 101 in high-risk populations, table e-10) 23, 34 (3C-Dijon, FHS, unpublished data), APOE e21 was significantly associated with BI: pooled OR 5 1.41 (1.09, 1.81) (p 5 0.008) ( figure 3B) .
APOE e2 and CMB. APOE e21 and CMB. In a metaanalysis including 7 studies (n 5 5,389, 4,508 in the general population, 881 in high-risk populations, figure e-3, 12, 21, 43, 44 APOE e21 and incident CMB. One study e42 (n 5 197 in high-risk populations) found a significant association between APOE e21 and incident CMB (table e-12), while another study did not (n 5 563 in the general population) e41 (table e-12).
DISCUSSION In this systematic review and metaanalysis comprising 42 studies on 29,965 participants, APOE e41 (mostly APOE e44) and APOE e21 genotypes were associated with increasing WMH load, APOE e41 genotype was associated with an increased prevalence of CMB, especially lobar, and APOE e21 genotype was associated with a higher frequency of BI.
One previous systematic review had examined the association between APOE e4 carrier status and WMH burden, including 24 studies on 8,546 individuals, reporting no significant association. 45 An earlier qualitative review had reached a similar conclusion. 46 However, previous reviews did not examine the association of APOE e44 or APOE e2 with WMH. 45 Besides, since then, data from 12 additional studies on the association between APOE e4 carrier status and WMH burden have become available, thus increasing power to detect associations. Mechanisms underlying associations of APOE genotypes with WMH burden are unclear. 47 CAA, a condition characterized by Ab accumulation in the media of cerebral and leptomeningeal arterioles 48 that is highly prevalent in aging populations, 49 is one potential mediator. Indeed, although CAA primarily affects cortical arterioles, APOE e4-enhanced thickening of the affected arterial wall by amyloid deposits causes reduction of the vessel lumen, 48, 50 potentially leading to reduced blood flow in distal perfusion zones of the white matter. 51 Supporting this hypothesis, APOE e4 was recently shown to be associated with occipital distribution of WMH, a location where CAA predominates. 52 The vasculopathic abnormalities associated with the APOE e2 allele in CAA patients, 50 including fibrinoid necrosis and blood-brain barrier damage, 53 might also affect small arteries in the white matter. 54 ApoE also plays a key role in lipid metabolism, but it is unclear whether APOE isoforms differentially influence lipid metabolism in the brain, 1 and the relationship between lipid levels and white matter disease is not well established. 27 Inflammation may also contribute to the observed relation of APOE e2 and APOE e4 with increasing WMH burden. 55 To date, no meta-analysis has evaluated the relationship between APOE e polymorphism and MRIdefined BI, to our knowledge. The absence of a significant association between APOE e4 and BI is in line with the lack of robust association between APOE e4 and ischemic stroke found in a recent meta-analysis, 7 although we may have been underpowered for this phenotype. Interestingly, we found a significant association between APOE e2 and BI, consistent with the association between APOE e2 and WMH burden, especially dichotomized extensive WMH; additional studies are needed to explore this relationship further, including analyses focused on lacunar brain infarcts, a more homogeneous entity reflecting primarily small-artery disease.
A systematic review recently addressed the relationship between the APOE e polymorphism and CMB, including a meta-analysis on 7 studies. 56 In line with our results, they found that APOE e4 carriers had a significantly increased risk of having at least one CMB compared to APOE e33 carriers, 56 with a stronger association for lobar CMB. They did not find a significant relationship between APOE e2 and CMB, regardless of their location. Their review did not consider recessive models, and we included 3 additional studies in our meta-analysis.
We observed a significant association of APOE e41 with CMB, which was even stronger for APOE e44. The association of APOE e4 with an increased risk of CMB, especially lobar, is consistent with recent data showing a significant relationship between APOE e4 and lobar ICH. 7, 8 The association of APOE e4 with intracerebral bleeding is thought to be primarily mediated by CAA, 8 representing a major cause of ICH in older individuals. 57 Histopathologic data suggest that APOE e4 enhances Ab deposition in the vessel wall. 50 Although we did not identify any significant association of APOE e2 with CMB, the sample size was smaller and for lobar CMB there was a trend for an association in the same direction as for APOE e4. APOE e2 has been associated with an increased risk of lobar ICH, 8 and with larger hematoma volumes, 9 possibly by increasing vessel wall damage caused by Ab deposition, 9 thus leading to increased vulnerability of vessels surrounding the hematoma. 50 Hence e2 carriers Meta-analysis of studies testing the association between APOE e21 and white matter hyperintensities burden and between APOE e21 and brain infarcts (A) Meta-analysis of studies testing the association between APOE e21 and white matter hyperintensities (WMH) burden. Fixed-effects inverse variance-weighted meta-analysis for studies on APOE e21 and continuous WMH (providing standardized mean differences) (heterogeneity test: I² 5 41%, p 5 0.17) (i); all studies are from the general population. Fixed-effects inverse variance-weighted meta-analysis for APOE e21 and dichotomized WMH (heterogeneity test: I² 5 45%, p 5 0.14) (ii). For secondary analysis using a random-effects model, see figure e-8. (B) Meta-analysis of studies testing the association between APOE e21 and brain infarcts (BI). Fixed-effects inverse variance-weighted meta-analysis (heterogeneity test: I² 5 25%, p 5 0.26). For secondary analysis using random-effects model, see figure e-9. APOE e21 5 APOE e2 carrier status; FHS 5 Framingham Heart Study; OR 5 odds ratio; p 5 p value from inverse variance-weighted meta-analysis; p z score 5 p value from sample size-weighted z score-based meta-analysis; SMD 5 standardized mean difference; Sydney MAS 5 Sydney Memory and Ageing Study.
might be more predisposed to larger, symptomatic hematomas but not microhemorrhages. This is the largest systematic review and meta-analysis on the association of the APOE e polymorphism with several MRI markers of CVD. A substantial effort was made to obtain additional unpublished information by contacting authors. In contrast with previous reviews, we have studied concomitantly several markers of ischemic and hemorrhagic CVD. Moreover, we combined all studies on APOE and WMH, including studies using WMH as a continuous or dichotomous variable, by performing a sample size-weighted z scorebased meta-analysis, thus increasing sample size and power to detect associations. In addition, we have summarized information on the effect of APOE e2 and APOE e44, whenever available.
We were limited by the fact that most studies provided effect estimates for APOE e4 carriers vs noncarriers only, with varying reference groups. Many studies have used APOE e42 and APOE e22 as reference groups, rather than APOE e33, which may have reduced our power to detect associations. Indeed, the fact that the relationship of APOE e4 and APOE e2 with MRI markers of CVD appears to be in the same direction, including APOE e2 carriers in the reference group for APOE e4 carriers, and vice versa, might have attenuated differences. Although we accounted for statistical heterogeneity by using a random-effects model when appropriate, there were differences between studies concerning MRI characteristics, definition of MRI markers, and adjustment variables. The detection of CMB is strongly correlated with magnetic strength 58 and some studies included in this meta-analysis were performed on MRI scanners ,1.5 T; this may have led to an underestimation of CMB prevalence and consequently reduced power to detect associations. Populations differed in terms of age distribution and vascular risk profile, which was partly accounted for in secondary meta-analyses performed separately in the general population or in groups at high risk of cerebrovascular disease (figures 1A, 2A and B, e-3, e-4, e-6, e-7, and e-10). Of note, most individuals included in the meta-analyses were community participants, and, whenever possible, we have shown that significant associations were maintained when restricting analyses to the general population. The vast majority of studies were performed in Caucasians; given the large differences in APOE e allele distributions worldwide, 8 our results may not be generalizable to other ethnic groups. Finally, as in all systematic reviews and meta-analyses of published data, we cannot exclude some degree of publication bias, although we have tried to minimize it by systematically adding unpublished results from 3 large population-based samples. Confirmation of our findings could be obtained in the future by prospective meta-analyses within large consortia using harmonized phenotypic criteria and analytical models.
APOE e4 and APOE e2 were associated with increasing burden in MRI markers for both hemorrhagic and ischemic CVD. WMH, CMB, and lacunar BI (the vast majority of BI) are prominent features of cerebral small-vessel disease 59 and are strongly correlated in both community and hospital-based samples. 12, 21, 22 It is therefore expected that they may share some genetic determinants. 47 However, it is intriguing to note that APOE e2 was associated with an increased burden of MRI-based CVD, while it has a protective effect on the occurrence of AD. 60 Hence, while the association of APOE e4 with an increased burden of CVD could be partly contributing to the relationship between APOE e4 and AD, APOE e2 was associated with MRI markers of CVD in the opposite direction compared to AD.
Future studies evaluating simultaneously in the same dataset the association of APOE with MRI markers of ischemic and hemorrhagic CVD could help elucidate whether these associations are independent or reflect the strong correlation between the phenotypes. Examining neuropathologic correlates of MRI-based CVD and their association with APOE genotypes could also help in understanding the pathophysiologic link between APOE and CVD. Finally, studies focusing on the influence of age and hypertension on the relationship between APOE and CVD could further contribute to deciphering the complex relationship of APOE with vascular brain aging. 2, 26 
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